Molecular mechanism of anti-prostate cancer activity of Scutellaria Baicalensis extract

Nutrition and Cancer

Volumn 57, Issue 1, 2007, Pages 100-110

  Ye, Fei ^a   Jiang, Shiquan ^a   Volshonok, Helen ^a   Wu, Josephine ^a   Zhang, David Y ^a,b  

^a NEW YORK UNIVERSITY   (United States)

^b Molecular Pathology Laboratory Network Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLINE; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; PROSTATE SPECIFIC ANTIGEN; SCUTELLARIA BAICALENSIS EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CELL STRAIN LNCAP; CHINESE HERB; CHINESE MEDICINE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PROSTATE CANCER; PROTEIN EXPRESSION; SCUTELLARIA BAICALENSIS; TUMOR VOLUME;

ANIMALIA; SCUTELLARIA BAICALENSIS;

EID: 34249906468     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580701268352     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al.: Cancer statistics, 2006. CA Cancer J Clin 56, 106-130, 2006.
2. Chu KC, Tarone RE, and Freeman HP: Trends in prostate cancer mortality among black men and white men in the United States. Cancer 97, 1507-1516, 2003.
3. Cho D, Di Blasio C, Rhee A, and Kattan M: Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT). Urol Oncol 21, 282-291, 2003.
4. Eton D and Lepore S: Prostate cancer and health-related quality of life: a review of the literature. Psychooncology 11, 307-326, 2002.
5. Eisenberg D, Davis R, Ettner S, Appel S, Wilkey S, et al.: Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280, 1569-1575, 1998.
6. Zimmerman R: Prevalence of complementary medicine in urologic practice: a review of recent studies with emphasis on use among prostate cancer patients. Urol Clin North Am 29, 1-9, 2002.
7. Pfeifer B, Pirani SR, Hamann S, and Klippel K: PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer. BJU Int 85, 481-485, 2000.
8. de la Taille A, Buttyan R, Hayek O, Bagiella E, Shabsigh A, et al.: Herbal therapy PC-SPES: In vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 164, 1229-1234, 2000.
9. Small E, Frohlich M, Bok R, Shinohara K, Grossfeld G, et al.: Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 18, 3595-3603, 2000.
10. Ye F, Xui L, Yi J, Zhang W, and Zhang DY: Anticancer activity of Scutellaria baicalensis and its potential mechanism. J Altern Complement Med 8, 567-572, 2002.
11. Zhang DY, Wu J, Ye F, Xue L, Jiang S, et al.: Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis. Cancer Res 63, 4037-4043, 2003.
12. Kase Y, Saitoh K, Ishige A, and Komatsu Y: Mechanisms by which hange-shashin-to reduces prostaglandin E2 levels. Biol Pharm Bull 21, 1277-1281, 1998.
13. Chi YS, Lim H, Park H, and Kim HY: Effects of wogonin, a plant flavone from Scutellaria radix, on skin inflammation: in vivo regulation of inflammation-associated gene expression. Biochem Pharmacol 66, 1271-1278, 2003.
14. Fujita H, Koshida K, Keller E, Takahashi Y, Yoshimito T, et al.: Cyclooxygenase-2 promotes prostate cancer progression. Prostate 53, 232-240, 2002.
15. Attiga F, Fernandez P, Weeraratna A, Manyak M, and Patierno S: Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 60, 4629-4637, 2000.
16. Liu X, Kirschenbaum A, Lu M, Yao S, Klausner A, et al.: Prostaglandin E2 stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/gp 130/stat-3 signaling pathway. Biochem Biophys Res Commun 290, 249-255, 2002.
17. Tjandrawinata R and Hughes-Fulford M: Up-regulation of cyclooxyenase-2 by product-prostaglandin E2. Adv Exp Med Biol 407, 163-170, 1997.
18. Chen Y, Martinez L, LaCava M, Coghlan L, and Conti C: Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1. Oncogene 16, 1913-1920, 1998.
19. Chen Y, Robles A, Martinez L, Liu F, Gimenez-Conti I, et al.: Expression of G1 cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced prostate proliferation in castrated rats. Cell Growth Differ 7, 1571-1578, 1996.
20. Ye F, Wang H, Jiang S, Wu J, Shao J, et al.: Quality evaluation of commercial extracts of Scutellaria baicalensis. Nutr Cancer 49, 217-222, 2004.
21. Schwarz R, Donohue C, Sadava D, and Kane S: Pancreatic cancer in vitro toxicity mediated by Chinese herbs SPES and PC-SPES: implications for monotherapy and combination treatment. Cancer Lett 189, 59-68, 2003.
22. Lu X, Guo J, and Hsieh T: PC-SPES inhibits cell proliferation by modulating p21, cyclins D, E and B and multiple cell cycle-related genes in prostate cancer cells. Cell Cycle 2, 59-63, 2003.
23. Navarro D, Luzardo O, Fernandez L, Chesa N, and Diaz-Chico B: Transition to androgen-independence in prostate cancer. J Steroid Biochem Mol Biol 81, 191-201, 2002.
24. Gau J, Salter R, Krill D, Grove M, and Becich M: The biosynthesis and secretion of prostate-specific antigen in LNCaP cells. Cancer Res 57, 3830-3834, 1997.
25. Chen Y, Shen S, Chen L, Lee T, and Yang L: Wogonin, baicalin, and baicalein inhibition of inducible nitric oxide synthase and cyclooxygenase-2 gene expressions induced by nitric oxide synthase inhibitors and lipopolysaccharide. Biochem Pharmacol 61, 1417-1427, 2001.
26. Pecher S, Pflug B, Brink A, and Nelson J: Endothelin A receptor blockade does not alter PSA secretion in prostate cancer cell lines. Prostate 60, 175-177, 2004.
27. Bonham M, Posakony J, Coleman I, Montgomery B, Simon J, et al.: Characterization of chemical constituents in Scutellaria baicalensis with antiandrogenic and growth-inhibitory activities toward prostate carcinoma. Clin Cancer Res 11, 3905-3914, 2005.
28. Hsu A, Ching T, Wang D, Song X, Rangnekar V, et al.: The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking akt activation in human prostate cancer cells independently of bcl-2. J Biol Chem 275, 11397-11403, 2000.
29. Song X, Lin H, Johnson A, Tseng P, Yang Y, et al.: Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. JNCI 94, 585-591, 2002.
30. Schinella GR, Tournier HA, Prieto JM, Mordujovich de Buschiazzo P, et al.: Antioxidant activity of anti-inflammatory plant extracts. Life Sci 70, 1023-1033, 2002.
31. Chung V, Tattersall M, and Cheung H: Interactions of a herbal combination that inhibits growth of prostate cancer cells. Cancer Chemother Pharmacol 53, 384-390, 2004.
32. Karan D, Kelly D, Rizzino A, Lin M, and Batra S: Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis 23, 967-975, 2002.
33. Lu S, Tsai S, and Tsai M: Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res 57, 4511-4516, 1997.
34. Lu S, Liu M, Epner D, Tsai S, and Tsai M: Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 13, 376-384, 1999.
35. Bonham M, Arnold H, Montgomery B, and Nelson P: Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma. Cancer Res 62, 3920-3924, 2002.
36. Shapiro G: Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 10, 4270-4275, 2004.
37. Dawson N and Slovin S: Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer. Urology 62, 102-118, 2003.
38. Chen Y and Hughes-Fulford M: Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer cells. Br J Cancer 82, 2000-2006, 2000.
39. Hughes-Fulford M, Chen Y, and Tjandrawinata R: Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. Carcinogenesis 22, 701-707, 2001.
40. Pan Y, Zhang J, Gazi M, and Young C: The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-jun in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 12, 769-774, 2003.
41. Guo C, Luttrell L, and Price D: Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines. J Urol 163, 1027-1032, 2000.
42. Pruthi R, Derksen J, and Moore D: A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Br J Urol 93, 275-278, 2004.